Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside

被引：46

作者：

Bruno, B

Giaccone, L

Rotta, M

Anderson, K

Boccadoro, M

机构：

[1] Univ Turin, Div Ematol, Osped S Giovanni Battist, I-10126 Turin, Italy

[2] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

LEUKEMIA | 2005年 / 19卷 / 10期

关键词：

mutliple myeloma; new drugs; signaling pathways;

D O I：

10.1038/sj.leu.2403905

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma remains an incurable plasma cell neoplasm. New insights into its pathogenesis have identified signaling pathways that have become potential therapeutic targets. It has clearly been established that intracellular regulatory proteins and interactions between malignant plasma cells and the bone marrow microenvironment play an important role in their survival and drug resistance. Several new agents associated with molecular targets are currently being investigated to design new treatment strategies aimed at prolonging survival and improving quality of life. This review illustrates their mechanisms of action and the possible future clinical applications.

引用

收藏

页码：1729 / 1738

页数：10

相关论文

共 58 条

[1]

Akiyama M, 2002, CANCER RES, V62, P3876

[2] Aetiology of bone disease and the role of bisphosphonates in multiple myeloma [J].

Ashcroft, AJ ;

Davies, FE ;

Morgan, GJ .

LANCET ONCOLOGY, 2003, 4 (05) :284-292

[3] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[4] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[5]

Berenson J, 1996, BRIT J CLIN PRACT, P5

[6] Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma [J].

Borad, MJ ;

Swift, R ;

Berenson, JR .

LEUKEMIA, 2005, 19 (01) :154-156

[7] New drugs for treatment of multiple myeloma [J].

Bruno, B ;

Rotta, M ;

Giaccone, L ;

Massaia, M ;

Bertola, A ;

Palumbo, A ;

Boccadoro, M .

LANCET ONCOLOGY, 2004, 5 (07) :430-442

[8] Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma [J].

Cavo, M ;

Zamagni, E ;

Tosi, P ;

Tacchetti, P ;

Cellini, C ;

Cangini, D ;

de Vivo, A ;

Testoni, N ;

Nicci, C ;

Terragna, C ;

Grafone, T ;

Perrone, G ;

Ceccolini, M ;

Tura, S ;

Baccarani, M .

BLOOD, 2005, 106 (01) :35-39

[9] Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells [J].

Chatterjee, M ;

Stühmer, T ;

Herrmann, P ;

Bommert, K ;

Dörken, B ;

Bargou, RC .

BLOOD, 2004, 104 (12) :3712-3721

[10] Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly [J].

Cohen, HJ ;

Crawford, J ;

Rao, MK ;

Pieper, CF ;

Currie, MS .

AMERICAN JOURNAL OF MEDICINE, 1998, 104 (05) :439-444

← 1 2 3 4 5 6 →